HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on TScan Therapeutics (NASDAQ:TCRX) and maintained a $15 price target.
August 14, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TScan Therapeutics (NASDAQ:TCRX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $15.
The reiteration of a 'Buy' rating and a maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100